- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: IMCgp100 is an immunotherapeutic antibody/peptide fusion, comprising a soluble T cell receptor (TCR) specific for the HLA-A2 restricted melanoma-associated antigen gp100, fused to an anti-CD3 single chain antibody fragment (scFv) [1,3]. This belongs to a novel class of immunotherapeutics termed ImmTACs (Immune Mobilising mTCR against Cancer) which are designed to override immune tolerance to cancer and mobilise T cells to kill cancer cells.
1. Bossi G, Buisson S, Oates J, Jakobsen BK, Hassan NJ. (2014)
ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells.
Cancer Immunol. Immunother., 63 (5): 437-48. [PMID:24531387]
2. Li Y, Moysey R, Molloy PE, Vuidepot AL, Mahon T, Baston E, Dunn S, Liddy N, Jacob J, Jakobsen BK et al.. (2005)
Directed evolution of human T-cell receptors with picomolar affinities by phage display.
Nat. Biotechnol., 23 (3): 349-54. [PMID:15723046]
3. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K et al.. (2012)
Monoclonal TCR-redirected tumor cell killing.
Nat. Med., 18 (6): 980-7. [PMID:22561687]